PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
- Conditions
- Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
- Interventions
- Drug: Matching placebo
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 261
- Registration Number
- NCT05248997
- Locations
- 🇺🇸
San Diego Clinical Research Center, La Mesa, California, United States
🇺🇸Velocity Clinical San Diego, La Mesa, California, United States
🇺🇸National Research Institute, Panorama City, California, United States
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
- Conditions
- Multiple Myeloma
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05238311
PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors
- Conditions
- Urothelial CancerAdvanced Solid TumorsGastroesophageal Junction CancerGastric CancerNon Small Cell Lung CancerHead and Neck Squamous Cell Carcinomas
- Interventions
- Biological: Sasanlimab
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT05233436
- Locations
- 🇺🇸
Napa Research, Margate, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
Voxelotor Brain Oxygenation and Neurocognitive Study
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05228821
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸The Children's Hospital at Montefiore, Bronx, New York, United States
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
- Conditions
- BCMAElranatamabRelapsed Multiple MyelomaRefractory Multiple MyelomaMultiple MyelomaBispecificBCMA-CD3 BispecificMyelomaPF-06863135MagnetisMM-8
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 39
- Registration Number
- NCT05228470
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Peking University Third Hospital, Beijing, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Voxelotor Neurocognitive Function Study
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05228834
- Locations
- 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza
- Conditions
- Influenza, Human
- Interventions
- Biological: PF-07836394 Influenza saRNABiological: PF-07836396 Influenza saRNABiological: PF-07852352 Influenza saRNA 1Biological: PF-07836395 Influenza saRNABiological: PF-07867246 Influenza saRNABiological: PF-07915048 Influenza saRNABiological: PF-07836391 Influenza saRNABiological: PF-07871987 Influenza saRNABiological: PF-07914705 Influenza saRNABiological: PlaceboBiological: Quadrivalent influenza vaccine (QIV)
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 442
- Registration Number
- NCT05227001
- Locations
- 🇺🇸
Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States
🇺🇸Pioneer Heart Institute, Lincoln, Nebraska, United States
🇺🇸Arizona Heart Rhythm Center, Phoenix, Arizona, United States
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
- Conditions
- Head and Neck CancerBreast Cancer
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT05226871
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, Beijing, China
🇺🇦Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council, Dnipro, Ukraine
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
- Conditions
- Moderate Hepatic ImpairmentSevere Hepatic ImpairmentHealthy Volunteers
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05224609
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸Genesis Clinical Research, LLC, Tampa, Florida, United States
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 107
- Registration Number
- NCT05217446
- Locations
- 🇨🇦
Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada
🇵🇱Przychodnia Lekarska KOMED, Konin, Wielkopolskie, Poland
🇵🇱Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza, Brzozow, Poland